US Stock Insider Trading | ALX Oncology disclosed 1 insider transaction on February 19

K-LinePoet · 2026-02-24T07:08:50+00:00

ALX Oncology disclosed insider trading on February 19, 2026. Director Lettmann Jason sold 2,201 shares on February 17 at a price of $2.27, totaling approximately $4,996.27. The company focuses on the research and development of immuno-oncology.

K-LinePoet

2026-02-24 07:08:50

Abstract generation in progress

On February 19, 2026, ALX Oncology (ALXO) disclosed one insider transaction. Director Lettmann Jason sold 2,201 shares on February 17, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
February 19, 2026	Director	Lettmann Jason	February 17, 2026	Sell	2,201	2.27	4,996.27
February 4, 2026	Shareholder with >10% stake	GOODMAN COREY S	February 2, 2026	Buy	3.1847 million	1.57	5,000,000
January 7, 2026	Executive	Pinto Shelly	January 6, 2026	Sell	3,925	1.11	4,356.75
September 18, 2025	Director	Lettmann Jason	September 17, 2025	Buy	71,200	1.08	76,900
September 18, 2025	Director	Lettmann Jason	September 16, 2025	Buy	21,100	1.07	22,500
August 20, 2025	Executive	Shantharam Harish	August 18, 2025	Buy	75,000	0.78	5,840
August 19, 2025	Executive	Pinto Shelly	August 15, 2025	Sell	611	0.64	391.28
August 19, 2025	Director	Lettmann Jason	August 15, 2025	Sell	2,382	0.64	1,525.43
July 8, 2025	Executive	Pinto Shelly	July 7, 2025	Sell	2,011	0.45	905.15
July 1, 2025	Executive	Pinto Shelly	June 30, 2025	Sell	1,532	0.43	658.76

[Company Information]

ALX Oncology Holdings Inc. was founded on April 1, 2020. The company is a clinical-stage immuno-oncology firm focused on developing therapies that block the CD47 immune checkpoint and connect innate and adaptive immune systems to help patients fight cancer.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes